---
title: "康方生物授出伊喜宁商业化权益  收授权费 8,000 万人民币"
description: "康方生物公布，与济川药业签订独占性商业化权益协议，据此，济川药业获授权在中国 (不包括香港、澳门及台湾) 拥有公司自主开发并已获批上市的伊喜宁 (伊努西单抗注射液) 独家商业化权益。本次合作，公司将获得 8,000 万人民币授权费，以及最高不超过 1,000 万人民币的里程碑付款。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274681417.md"
published_at: "2026-02-03T15:42:37.000Z"
---

# 康方生物授出伊喜宁商业化权益  收授权费 8,000 万人民币

> 康方生物公布，与济川药业签订独占性商业化权益协议，据此，济川药业获授权在中国 (不包括香港、澳门及台湾) 拥有公司自主开发并已获批上市的伊喜宁 (伊努西单抗注射液) 独家商业化权益。本次合作，公司将获得 8,000 万人民币授权费，以及最高不超过 1,000 万人民币的里程碑付款。

康方生物 (09926.HK) 公布，与济川药业 (600566.SH) 签订独占性商业化权益协议，据此，济川药业获授权在中国 (不包括香港、澳门及台湾) 拥有公司自主开发并已获批上市的伊喜宁 (伊努西单抗注射液) 独家商业化权益。

本次合作，公司将获得 8,000 万人民币授权费，以及最高不超过 1,000 万人民币的里程碑付款。

### Related Stocks

- [516820.CN - 平安中证医疗创新ETF](https://longbridge.com/zh-CN/quote/516820.CN.md)
- [159849.CN - 招商中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [588250.CN - 鹏华上证科创板生物医药ETF](https://longbridge.com/zh-CN/quote/588250.CN.md)
- [09926.HK - 康方生物](https://longbridge.com/zh-CN/quote/09926.HK.md)
- [159837.CN - 易方达中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [510660.CN - 华夏医药ETF](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [560600.CN - 方正富邦中证医药及医疗器械创新ETF](https://longbridge.com/zh-CN/quote/560600.CN.md)
- [159859.CN - 天弘国证生物医药ETF](https://longbridge.com/zh-CN/quote/159859.CN.md)
- [512010.CN - 易方达沪深300医药ETF](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [512290.CN - 国泰中证生物医药ETF](https://longbridge.com/zh-CN/quote/512290.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease | SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigation | [Link](https://longbridge.com/zh-CN/news/276765156.md) |
| Sunshine Lake Pharma Wins NMPA Nod to Trial First China-Developed Nipah Virus Antibody | Sunshine Lake Pharma has received approval from China's Center for Drug Evaluation to begin clinical trials for HEC-648  | [Link](https://longbridge.com/zh-CN/news/276716153.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-CN/news/276024005.md) |
| HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China | HBM Holdings (SEHK:2142) has entered an exclusive partnership with Solstice Oncology for its clinical asset HBM4003 outs | [Link](https://longbridge.com/zh-CN/news/276700073.md) |
| Palumbo Wealth Management LLC Buys New Stake in ProShares Ultra Nasdaq Biotechnology $BIB | Palumbo Wealth Management LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) during the third | [Link](https://longbridge.com/zh-CN/news/276735169.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。